Search

Displaying results 2341 - 2350 of 10000 in total
  1. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    [A246703] Pralatrexate was approved by the FDA on September 24, 2009. … [A246693] Compared to methotrexate, pralatrexate has better accumulation in cancer cells.

    Synonyms: N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid
  2. Drug

    Conivaptan

    go.drugbank.com/drugs/DB00872
    Approved

    It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). … Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin).

    Products: Vaprisol Dextrose In Plastic Container
  3. Drug

    Sulisobenzone

    go.drugbank.com/drugs/DB11185
    Approved

    Sulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations [F38]. … The UV-filter substance, sulisobenzone (BP-4) is widely used an ingredient in sunscreens and other personal care products [A32927], [L2668]. It falls under the drug category of _benzophenones_.

    Mixtures: 3-IN-1 Active Moisturizer
  4. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379] … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12

  5. Drug

    Prilocaine

    go.drugbank.com/drugs/DB00750
    ApprovedInvestigational

    Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165)

    Mixtures: LIDOCAINA E PRILOCAINA TEVA, LIDOCAINA E PRILOCAINA TEVASynonyms: alpha-n-Propylamino-2-methylpropionanilide, N-(2-Methylphenyl)-2-(propylamino)propanamide
  6. Drug

    AMGN-0007

    go.drugbank.com/drugs/DB06511
    Experimental

    Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.

  7. Drug

    Carbetocin

    go.drugbank.com/drugs/DB01282
    ApprovedInvestigational

    It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.

    Products: Carbetocin Aguettant 100 Mikrogramm/ml Injektionslösung in einer Fertigspritze
  8. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. … has made it a desirable therapeutic target in MF treatment.

  9. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    [L15331,L15336] Set to be substantially cheaper than other available SMA therapies,[L15351] risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless … Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA).

  10. Drug

    Sulfathiazole

    go.drugbank.com/drugs/DB06147
    ApprovedVet approvedWithdrawn

    It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.

    Synonyms: N(1)-2-Thiazolylsulfanilamide, 4-Amino-N-2-thiazolylbenzenesulfonamideMixtures: STREPTOSIL CON NEOMICINA, STREPTOSIL CON NEOMICINA